Immune Technology Corp

Immune Technology Corp is a private, early-revenue stage biotechnology company operating as a reagent and contract service provider in the immunology and infectious disease sectors. The company leverages a platform for producing high-quality viral antigens and antibodies to support global research efforts against pathogens like SARS-CoV-2, influenza, and Zika virus. Its business model combines the sale of catalog research products with custom service offerings, including protein production and antibody development. While not a therapeutic developer, IT positions itself as a critical enabler for diagnostic, vaccine, and therapeutic research within the virology field.

Platform for development and manufacture of viral antigens and anti-viral antibodies using E. coli, yeast, and mammalian expression systems. Offers custom services including polyclonal antibody production, plasmid production, protein production, and molecular biology services.

Operates in the crowded life science research tools market, competing with giants like Thermo Fisher Scientific, Abcam, and Sino Biological, as well as numerous specialized CROs and reagent companies. Differentiation is based on niche virology expertise, speed of response to new pathogens, and the combination of catalog products with custom services. Market position is that of a specialized niche player rather than a broad-line distributor.